Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine phosphate 19Cyclophosphamide 18Tacrolimus 17Peripheral Blood Stem Cell Transplantation 17Mycophenolic Acid 17Antilymphocyte Serum 14Busulfan 13Whole-Body Irradiation 12Methotrexate 11Cyclosporine 11Melphalan 7mogamulizumab 6Methylprednisolone 6Etoposide 6Bexarotene 6Sirolimus 5Radiotherapy 5Flow Cytometry 5Filgrastim 5sargramostim 4pembrolizumab 4Vorinostat 4Transplantation 4Therapeutics 4Rituximab 4Lenalidomide 4Brentuximab Vedotin 4Alemtuzumab 4thymoglobulin 3romidepsin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell, Cutaneous × sapacitabine × Clear all
NCT00476554 2021-12-22

A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

Cyclacel Pharmaceuticals, Inc.

Phase 2 Terminated
16 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡